These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
228 related articles for article (PubMed ID: 33506984)
41. Chronic urticaria: omalizumab and review of therapeutic options. Bergstrom KG J Drugs Dermatol; 2013 Jun; 12(6):715-6. PubMed ID: 23839196 [TBL] [Abstract][Full Text] [Related]
42. Omalizumab Updosing in Chronic Spontaneous Urticaria: an Overview of Real-World Evidence. Metz M; Vadasz Z; Kocatürk E; Giménez-Arnau AM Clin Rev Allergy Immunol; 2020 Aug; 59(1):38-45. PubMed ID: 32418171 [TBL] [Abstract][Full Text] [Related]
43. Determinants of omalizumab drug survival in a long-term daily practice cohort of patients with chronic urticaria. Spekhorst LS; van den Reek JMPA; Knulst AC; Röckmann H Allergy; 2019 Jun; 74(6):1185-1187. PubMed ID: 30593687 [No Abstract] [Full Text] [Related]
44. Efficacy and Safety of Omalizumab (Xolair) for Cholinergic Urticaria in Patients Unresponsive to a Double Dose of Antihistamines: A Randomized Mixed Double-Blind and Open-Label Placebo-Controlled Clinical Trial. Gastaminza G; Azofra J; Nunez-Cordoba JM; Baeza ML; Echechipía S; Gaig P; García BE; Labrador-Horrillo M; Sala-Cunill A; Brescó MS; Beristain A; Quiñones D; Donado CD; Zubeldia JM; Ferrer M J Allergy Clin Immunol Pract; 2019; 7(5):1599-1609.e1. PubMed ID: 30654196 [TBL] [Abstract][Full Text] [Related]
45. Biomarkers of chronic spontaneous urticaria and their clinical implications. Asero R; Cugno M Expert Rev Clin Immunol; 2021 Mar; 17(3):247-254. PubMed ID: 33496195 [No Abstract] [Full Text] [Related]
46. Omalizumab treatment in adolescents with chronic spontaneous urticaria: Efficacy and safety. Ocak M; Soyer O; Buyuktiryaki B; Sekerel BE; Sahiner UM Allergol Immunopathol (Madr); 2020; 48(4):368-373. PubMed ID: 32467066 [TBL] [Abstract][Full Text] [Related]
47. Efficacy of omalizumab treatment for pediatric chronic spontaneous urticaria: A multi-center retrospective case series. Ari A; Levy Y; Segal N; Maoz-Segal R; Benor S; Broides A; Horev A; Epstein-Rigbi N; Agmon-Levin N; Marcus N Pediatr Dermatol; 2020 Nov; 37(6):1051-1054. PubMed ID: 32951239 [TBL] [Abstract][Full Text] [Related]
48. Serum transglutaminase 2 activity as a potential biomarker of disease severity and response to omalizumab in chronic spontaneous urticaria. Bae Y; Kang SH; Park JO; Park GH; Choi JH Allergol Int; 2020 Apr; 69(2):304-306. PubMed ID: 31767272 [No Abstract] [Full Text] [Related]
49. Real-life data on the effectiveness and safety of omalizumab in monotherapy or combined for chronic spontaneous urticaria: a retrospective cohort study. Salman A; Ergun T; Gimenez-Arnau AM J Dermatolog Treat; 2020 Mar; 31(2):204-209. PubMed ID: 30821591 [No Abstract] [Full Text] [Related]
50. A retrospective analysis omalizumab treatment patterns in patients with chronic spontaneous urticaria: a real-world study in Belgium. Lapeere H; Baeck M; Stockman A; Sabato V; Grosber M; Moutschen M; Lambert J; Vandebuerie L; de Montjoye L; Rabijns H; Allewaert K; Schrijvers R J Eur Acad Dermatol Venereol; 2020 Jan; 34(1):127-134. PubMed ID: 31099916 [TBL] [Abstract][Full Text] [Related]
51. Omalizumab in chronic urticaria: a retrospective series of 15 cases. Armengot-Carbo M; Velasco-Pastor M; Rodrigo-Nicolas B; Pont-Sanjuan V; Quecedo-Estebanez E; Gimeno-Carpio E Dermatol Ther; 2013; 26(3):257-9. PubMed ID: 23742285 [TBL] [Abstract][Full Text] [Related]
52. Treatment with omalizumab or cyclosporine for resistant chronic spontaneous urticaria. Koski R; Kennedy KK Ann Allergy Asthma Immunol; 2017 Nov; 119(5):397-401. PubMed ID: 29150066 [No Abstract] [Full Text] [Related]
53. Hematologic parameters as biomarkers for antihistamine and omalizumab resistance in chronic spontaneous urticaria. Magen E; Waitman DA; Kahan NR Allergy Asthma Proc; 2021 Jan; 42(1):e17-e24. PubMed ID: 33404397 [No Abstract] [Full Text] [Related]
54. Experience with Omalizumab for the treatment of chronic spontaneous urticaria in a tertiary center: real life experience. Acar A; Gerceker Turk B; Ertam Sagduyu I; Ceylan C; Ozturk G; Unal I Cutan Ocul Toxicol; 2020 Sep; 39(3):249-253. PubMed ID: 32597235 [TBL] [Abstract][Full Text] [Related]
55. Antinuclear antibodies are common and linked to poor response to omalizumab treatment in patients with CSU. Ertaş R; Hawro T; Altrichter S; Özyurt K; Erol K; Ketenci Ertaş Ş; Maurer M Allergy; 2020 Feb; 75(2):468-470. PubMed ID: 31469912 [No Abstract] [Full Text] [Related]
56. Addition of omalizumab to antihistamine treatment in chronic urticaria: A real-world study in China. Chen YD; Maurer M; Yu M; Tu P; Zhao ZT Ann Allergy Asthma Immunol; 2020 Aug; 125(2):217-219. PubMed ID: 32371240 [No Abstract] [Full Text] [Related]
57. Antihistamine-resistant chronic spontaneous urticaria remains undertreated: 2-year data from the AWARE study. Maurer M; Costa C; Gimenez Arnau A; Guillet G; Labrador-Horrillo M; Lapeere H; Meshkova R; Savic S; Chapman-Rothe N Clin Exp Allergy; 2020 Oct; 50(10):1166-1175. PubMed ID: 32735720 [TBL] [Abstract][Full Text] [Related]
58. The response to treatment in chronic spontaneous urticaria depends on how it is measured. Weller K; Church MK; Metz M; Hawro T; Ohanyan T; Staubach P; Maurer M J Allergy Clin Immunol Pract; 2019; 7(6):2055-2056.e4. PubMed ID: 30731179 [No Abstract] [Full Text] [Related]
60. Dupilumab as a rescue therapy for a chronic urticaria patient who showed secondary failure to omalizumab. Sun Y; Lin SY; Lan CE Kaohsiung J Med Sci; 2022 Jun; 38(6):610-611. PubMed ID: 35394689 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]